# EBF1

## Overview
EBF1 (Early B-cell Factor 1) is a gene that encodes the EBF transcription factor 1, a pivotal protein in the regulation of B-cell development and differentiation. As a transcription factor, EBF1 is categorized as a pioneer factor due to its ability to bind to chromatin and initiate changes in chromatin accessibility, thereby activating B-cell-specific genes (Li2018Dynamic). The protein is characterized by a complex structure that includes a DNA-binding domain with a pseudoimmunoglobulin-like fold, a Zn knuckle motif, and a helix-loop-helix domain, all of which contribute to its function in DNA recognition and dimerization (Treiber2010Structure). EBF1 interacts with various proteins, including viral antigens and nuclear import receptors, which influence its role in transcriptional regulation and immune response (Glaser2017EBF1; Bayer2022Tnpo3). Clinically, mutations or alterations in the EBF1 gene are associated with B-cell acute lymphoblastic leukemia, highlighting its significance in maintaining normal B-cell function and preventing leukemic transformation (RamírezKomo2017Spontaneous; Ramamoorthy2020EBF1).

## Structure
The EBF1 protein, a transcription factor crucial for B-cell differentiation, exhibits a complex molecular structure. Its DNA-binding domain (DBD) spans amino acids 26-240 and forms a pseudoimmunoglobulin-like fold with a novel topology, similar to the Rel homology domains of NFAT and NF-kB (Treiber2010Structure). The DBD is characterized by a β sandwich structure, consisting of a four-stranded β sheet packed against a five-stranded sheet, with an α helix at the N terminus packing against the β structure (Treiber2010Structure). 

A unique feature of EBF1 is the Zn knuckle, a structural motif formed by a loop and three short helices stabilized by a zinc ion, which protrudes from the domain and participates in DNA recognition (Treiber2010Structure). The protein forms a symmetric dimer when bound to DNA, with each monomer contacting both half-sites of a palindromic sequence (Treiber2010Structure). 

EBF1 also contains a helix-loop-helix (HLH) domain that facilitates dimerization, forming a helix bundle reminiscent of dimerized HLH domains, although it diverges from canonical HLH domains (Treiber2010Structure). The TIG domain of EBF1 adopts an Ig-like fold and contributes to dimerization (Treiber2010Structure).

## Function
EBF1 (Early B-cell Factor 1) is a transcription factor that plays a pivotal role in B-cell development and differentiation. It functions as a pioneer transcription factor, capable of binding to chromatin and initiating changes in chromatin accessibility, which is crucial for activating B-cell-specific genes (Li2018Dynamic). EBF1 is involved in a regulatory network with other transcription factors such as PU.1, E2A, and Pax5, ensuring the establishment and maintenance of B-cell identity (Li2018Dynamic; Rothenberg2014Transcriptional).

EBF1's activity is essential for the expression of most B-cell genes and the rearrangement of immunoglobulin heavy and light chain genes, which are critical for B-cell receptor formation (Nutt2007The; Lukin2010Compound). It collaborates with transcription factors like RUNX1 to drive the expression of B-cell-specific genes, such as Cd79a, and to initiate V(D)J recombination, a process vital for B-cell development (Nutt2007The; Lukin2010Compound).

EBF1 also plays a role in repressing genes associated with alternative cell fates, thereby committing cells to the B-cell lineage (Li2018Dynamic). It is active in the nucleus, where it regulates gene expression by binding to specific DNA sequences, influencing the transcription of genes involved in immune response and cell cycle regulation (Hagman1993Cloning).

## Clinical Significance
Mutations or alterations in the EBF1 gene are significantly associated with various forms of leukemia, particularly B-cell acute lymphoblastic leukemia (B-ALL). EBF1 haploinsufficiency, where there is a reduction in gene dosage, is linked to high-risk, relapsed, and therapy-resistant B-ALL, especially in pediatric patients. This condition is often characterized by a low relapse-free survival rate (RamírezKomo2017Spontaneous). EBF1 deletions can disrupt the open reading frame, contributing to disease progression and chemotherapy resistance (RamírezKomo2017Spontaneous). In mouse models, EBF1 haploinsufficiency leads to increased DNA damage in pro-B cells due to reduced expression of DNA repair genes like Rad51, which is a direct target of EBF1 (Prasad2015Ebf1).

EBF1 also plays a role in safeguarding against leukemic transformation by regulating pathways such as IL-7 signaling and Myc expression. Alterations in EBF1, along with PAX5, can lead to impaired differentiation and cellular transformation, contributing to B-ALL (Ramamoorthy2020EBF1). In Ebf1 +/- Bcl-x L Tg mice, the loss of EBF1 is associated with the development of aggressive pre-B leukemia, characterized by neoplastic infiltrates in multiple organs (RamírezKomo2017Spontaneous). These findings underscore the critical role of EBF1 in maintaining normal B-cell differentiation and preventing leukemic transformation.

## Interactions
EBF1 (EBF transcription factor 1) is involved in various protein interactions that influence its function in B-cell development and differentiation. EBF1 interacts with the Epstein-Barr virus nuclear antigen 2 (EBNA2), forming complexes that facilitate EBNA2's binding to chromatin independently of CBF1. This interaction is crucial for the expression of viral target genes in B cells (Glaser2017EBF1). EBF1 also interacts with the nuclear import receptor Transportin-3 (Tnpo3), which is essential for its function under antagonistic Notch signaling conditions. This interaction involves the immunoglobulin-like fold domain of EBF1 (Bayer2022Tnpo3).

EBF1 forms complexes with other transcription factors such as MEF2C and interacts with the CCR4/NOT complex, which may diversify its function in transcriptional regulation (Bayer2022Tnpo3). It also binds to multi-zinc finger proteins ZNF423 and ZNF521, which can inhibit its dimerization and DNA binding, potentially promoting tumorigenesis (Bayer2022Tnpo3). EBF1's interaction with TET2 suggests a role in influencing DNA methylation patterns, particularly in the context of IDH-mutant cancers (Guilhamon2013Metaanalysis).


## References


[1. (Treiber2010Structure) Nora Treiber, Thomas Treiber, Georg Zocher, and Rudolf Grosschedl. Structure of an ebf1:dna complex reveals unusual dna recognition and structural homology with rel proteins. Genes &amp; Development, 24(20):2270–2275, September 2010. URL: http://dx.doi.org/10.1101/gad.1976610, doi:10.1101/gad.1976610. This article has 47 citations.](https://doi.org/10.1101/gad.1976610)

[2. (Li2018Dynamic) Rui Li, Pierre Cauchy, Senthilkumar Ramamoorthy, Sören Boller, Lukas Chavez, and Rudolf Grosschedl. Dynamic ebf1 occupancy directs sequential epigenetic and transcriptional events in b-cell programming. Genes &amp; Development, 32(2):96–111, January 2018. URL: http://dx.doi.org/10.1101/gad.309583.117, doi:10.1101/gad.309583.117. This article has 81 citations.](https://doi.org/10.1101/gad.309583.117)

[3. (Nutt2007The) Stephen L. Nutt and Barbara L. Kee. The transcriptional regulation of b cell lineage commitment. Immunity, 26(6):715–725, June 2007. URL: http://dx.doi.org/10.1016/j.immuni.2007.05.010, doi:10.1016/j.immuni.2007.05.010. This article has 303 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.immuni.2007.05.010)

[4. (Bayer2022Tnpo3) Marc Bayer, Sören Boller, Senthilkumar Ramamoothy, Nikolay Zolotarev, Pierre Cauchy, Norimasa Iwanami, Gerhard Mittler, Thomas Boehm, and Rudolf Grosschedl. Tnpo3 enables ebf1 function in conditions of antagonistic notch signaling. Genes &amp; Development, 36(15–16):901–915, August 2022. URL: http://dx.doi.org/10.1101/gad.349696.122, doi:10.1101/gad.349696.122. This article has 4 citations.](https://doi.org/10.1101/gad.349696.122)

[5. (Lukin2010Compound) Kara Lukin, Scott Fields, Desiree Lopez, Marie Cherrier, Kristina Ternyak, Julita Ramírez, Ann J. Feeney, and James Hagman. Compound haploinsufficiencies ofebf1andrunx1genes impede b cell lineage progression. Proceedings of the National Academy of Sciences, 107(17):7869–7874, April 2010. URL: http://dx.doi.org/10.1073/pnas.1003525107, doi:10.1073/pnas.1003525107. This article has 42 citations.](https://doi.org/10.1073/pnas.1003525107)

[6. (RamírezKomo2017Spontaneous) J A Ramírez-Komo, M A Delaney, D Straign, K Lukin, M Tsang, B M Iritani, and J Hagman. Spontaneous loss of b lineage transcription factors leads to pre-b leukemia in ebf1+/–bcl-xltg mice. Oncogenesis, 6(7):e355–e355, July 2017. URL: http://dx.doi.org/10.1038/oncsis.2017.55, doi:10.1038/oncsis.2017.55. This article has 5 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/oncsis.2017.55)

[7. (Prasad2015Ebf1) Mahadesh A. J. Prasad, Jonas Ungerbäck, Josefine Åhsberg, Rajesh Somasundaram, Tobias Strid, Malin Larsson, Robert Månsson, Ayla De Paepe, Henrik Lilljebjörn, Thoas Fioretos, James Hagman, and Mikael Sigvardsson. Ebf1 heterozygosity results in increased dna damage in pro-b cells and their synergistic transformation by pax5 haploinsufficiency. Blood, 125(26):4052–4059, June 2015. URL: http://dx.doi.org/10.1182/blood-2014-12-617282, doi:10.1182/blood-2014-12-617282. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2014-12-617282)

[8. (Rothenberg2014Transcriptional) Ellen V. Rothenberg. Transcriptional control of early t and b cell developmental choices. Annual Review of Immunology, 32(1):283–321, March 2014. URL: http://dx.doi.org/10.1146/annurev-immunol-032712-100024, doi:10.1146/annurev-immunol-032712-100024. This article has 175 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1146/annurev-immunol-032712-100024)

[9. (Hagman1993Cloning) J Hagman, C Belanger, A Travis, C W Turck, and R Grosschedl. Cloning and functional characterization of early b-cell factor, a regulator of lymphocyte-specific gene expression. Genes &amp; Development, 7(5):760–773, May 1993. URL: http://dx.doi.org/10.1101/gad.7.5.760, doi:10.1101/gad.7.5.760. This article has 213 citations.](https://doi.org/10.1101/gad.7.5.760)

[10. (Guilhamon2013Metaanalysis) Paul Guilhamon, Malihe Eskandarpour, Dina Halai, Gareth A. Wilson, Andrew Feber, Andrew E. Teschendorff, Valenti Gomez, Alexander Hergovich, Roberto Tirabosco, M. Fernanda Amary, Daniel Baumhoer, Gernot Jundt, Mark T. Ross, Adrienne M. Flanagan, and Stephan Beck. Meta-analysis of idh-mutant cancers identifies ebf1 as an interaction partner for tet2. Nature Communications, July 2013. URL: http://dx.doi.org/10.1038/ncomms3166, doi:10.1038/ncomms3166. This article has 146 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms3166)

[11. (Ramamoorthy2020EBF1) Senthilkumar Ramamoorthy, Kohei Kometani, Josip S. Herman, Marc Bayer, Sören Boller, Joy Edwards-Hicks, Haribaskar Ramachandran, Rui Li, Ramon Klein-Geltink, Erika L. Pearce, Dominic Grün, and Rudolf Grosschedl. Ebf1 and pax5 safeguard leukemic transformation by limiting il-7 signaling, myc expression, and folate metabolism. Genes &amp; Development, 34(21–22):1503–1519, October 2020. URL: http://dx.doi.org/10.1101/gad.340216.120, doi:10.1101/gad.340216.120. This article has 19 citations.](https://doi.org/10.1101/gad.340216.120)

[12. (Glaser2017EBF1) Laura V. Glaser, Simone Rieger, Sybille Thumann, Sophie Beer, Cornelia Kuklik-Roos, Dietmar E. Martin, Kerstin C. Maier, Marie L. Harth-Hertle, Björn Grüning, Rolf Backofen, Stefan Krebs, Helmut Blum, Ralf Zimmer, Florian Erhard, and Bettina Kempkes. Ebf1 binds to ebna2 and promotes the assembly of ebna2 chromatin complexes in b cells. PLOS Pathogens, 13(10):e1006664, October 2017. URL: http://dx.doi.org/10.1371/journal.ppat.1006664, doi:10.1371/journal.ppat.1006664. This article has 28 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.ppat.1006664)